Bioxel Pharma Awards Stock Options to its Directors, Officers and Employees.STE-FOY, Quebec -- Bioxel Pharma Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:BIP BIP - An incorrect singular of BIPS. One billion instructions per second is 1 BIPS, not 1 BIP. ) a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, announced today that its Board of Directors had awarded on February 27, 2006, 640,000 common share purchase options at an exercise price of $0.54 per share, being the closing price of the common shares of Bioxel on the TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. on the last business day preceding the date of grant, to its directors, officers and employees under Bioxel's stock option plan. The 640,000 common share purchase options vested on June 27, 2006 will expire on February 26, 2011. Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. , Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy. The TSX Venture Exchange has not reviewed the contents of this pre ss release and accepts no responsibility for the adequacy or the accur acy thereof. Bioxel Pharma Inc. (TSX VENTURE:BIP) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion